You can buy or sell OCUL and other stocks, options, ETFs, and crypto commission-free!
Ocular Therapeutix, Inc. Common Stock, also called Ocular Therapeutix, is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Read More Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
52 Week High
52 Week Low
Yahoo FinanceMay 21
Chevron, Sprint, Ocular Therapeutix, and More: Why These Stocks Are in the Spotlight
All eyes are on the tech sector after President Trump escalated the trade war with China by putting Chinese crown jewel Huawei on a blacklist.
Seeking AlphaMay 10
Ocular Therapeutix, Inc. CEO Antony Mattessich on Q1 2019 Results - Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:04 AM ET Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q1 2019 Earnings Conference Call May 10, 2019, 08:30 AM ET Company Participants Antony Mattessich - President and CEO Donald Notman - CFO Scott Corning - SVP, Commercial Michael Goldstein - CMO Conference Call Participants Dan Leone - Raymond James Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. Thank you for standing by. And welcome to the Ocular Therapeutix First Quarter Earnings Confe...
Yahoo FinanceMay 2
Ocular Therapeutix™ To Report First Quarter 2019 Financial Results
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix™, Inc. (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2019 financial results on Friday, May 10, 2019. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 8:30 a.m. Eastern Tim...
-$0.42 per share
-$0.45 per share